Intestinal Infection by Clostridioides difficile (ICD-11: 1A04)

1. Introduction

Intestinal infection by Clostridioides difficile represents one of the most significant complications associated with antimicrobial use and prolonged hospitalization. This gram-positive, anaerobic, spore-forming bacillus has become an increasingly clinical challenge in healthcare settings worldwide, affecting thousands of patients annually and generating substantial costs to health systems.

The clinical importance of this infection lies in its ability to cause everything from mild diarrhea to severe pseudomembranous colitis, toxic megacolon, and in extreme cases, death. The pathogenic mechanism involves disruption of the balance of normal intestinal microbiota, usually caused by broad-spectrum antibiotics, allowing C. difficile to colonize the colon and release toxins that cause intense inflammation and damage to the intestinal mucosa.

The impact on public health is considerable, especially in hospital settings and long-term care institutions, where transmission between patients can occur through resistant spores that persist on surfaces and equipment. The recurrent nature of the infection, which can return in up to one-third of cases even after appropriate treatment, adds complexity to clinical management and increases the burden on health systems.

Correct coding using ICD-11 is critical for accurate epidemiological tracking, appropriate resource allocation, implementation of infection control measures, and for research seeking to develop new therapeutic and preventive strategies. Appropriate documentation allows identification of outbreaks, evaluation of treatment protocol efficacy, and justification of isolation measures and contact precautions necessary to prevent hospital dissemination.

2. Correct ICD-11 Code

Code: 1A04

Description: Intestinal infection due to Clostridioides difficile

Parent category: Bacterial intestinal infections

Official definition: Clostridioides difficile is a gram-positive, anaerobic, spore-forming bacillus responsible for the development of diarrhea and colitis associated with antibiotics. Colitis due to C. difficile results from a disturbance of the normal bacterial flora of the colon, colonization by C. difficile, and release of toxins that cause inflammation and damage to the mucosa.

This specific code should be used when there is laboratory confirmation or strong clinical suspicion of C. difficile infection, typically manifesting as watery diarrhea, abdominal cramping, and fever in patients with a recent history of antimicrobial use. Code 1A04 encompasses all manifestations of infection, from mild cases to severe pseudomembranous colitis, not requiring additional subcategorization in the current ICD-11 structure.

The use of this code is fundamental to differentiate this specific entity from other bacterial intestinal infections, allowing appropriate monitoring of cases, implementation of specific treatment protocols, and adoption of appropriate infection control measures, including contact precautions and environmental decontamination with sporicidal agents.

3. When to Use This Code

Code 1A04 should be applied in specific clinical scenarios where there is documented evidence or strong suspicion of Clostridioides difficile infection:

Scenario 1: Antibiotic-associated diarrhea with positive test A 68-year-old patient admitted for pneumonia, treated with fluoroquinolones for seven days, develops profuse watery diarrhea (more than three liquid bowel movements in 24 hours) on the tenth day of hospitalization. C. difficile toxin test in stool returns positive. This is the classic scenario requiring the use of code 1A04, regardless of initial symptom severity.

Scenario 2: Pseudomembranous colitis confirmed by colonoscopy Patient with persistent diarrhea following clindamycin use for dental infection. Colonoscopy reveals characteristic yellowish plaques adhered to the colonic mucosa, with pseudomembrane appearance. Even without toxin testing available, the characteristic endoscopic appearance justifies the use of code 1A04, as pseudomembranous colitis is practically pathognomonic of this infection.

Scenario 3: Documented recurrent infection Patient previously treated for C. difficile infection with metronidazole, presents with new episode of watery diarrhea three weeks after completing treatment. New test confirms presence of toxin. This recurrent episode should also be coded as 1A04, and it is important to document in the medical record that this is a recurrence to guide therapeutic decisions.

Scenario 4: Toxic megacolon secondary to C. difficile Patient with severe C. difficile infection develops marked abdominal distension, signs of systemic toxicity, and radiological imaging showing colonic dilation greater than 6 centimeters. This severe complication is still primarily coded as 1A04, and additional codes may be added for toxic megacolon and its complications.

Scenario 5: Community-acquired infection Patient without recent hospitalization, but with home use of amoxicillin-clavulanate for sinusitis, develops diarrhea and abdominal cramping. Stool test confirms toxigenic C. difficile. Although less common, community-acquired infection also uses code 1A04, and it is relevant to document the source for epidemiological purposes.

Scenario 6: Asymptomatic carrier who develops symptoms Patient colonized by C. difficile (detected on screening) remained asymptomatic, but after a new course of antibiotics for urinary tract infection, develops clinical manifestations of colitis. When there is a transition from colonization to symptomatic infection, code 1A04 is appropriate.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 1A04 should not be applied, avoiding coding errors that compromise epidemiological data and clinical management:

Specific exclusion: Necrotizing enterocolitis of the newborn When a neonate develops necrotizing enterocolitis, even if C. difficile is detected in stool, the appropriate code is the one specific for necrotizing enterocolitis (code related to the neonatal system), not 1A04. Necrotizing enterocolitis has distinct pathophysiology, risk factors specific to prematurity, and differentiated management, justifying separate coding.

Asymptomatic colonization Patients who present positive tests for C. difficile in stool but remain completely asymptomatic should not receive code 1A04. Colonization is relatively common, especially in hospital settings, and does not constitute infection. These cases do not require treatment or coding as active infection.

Diarrhea from other causes in colonized patient When a patient colonized by C. difficile develops diarrhea from another clearly identified etiology (for example, documented viral gastroenteritis, osmotic effect of medications, active inflammatory bowel disease), code 1A04 should not be used, even if the test for C. difficile is positive. The presence of the organism does not imply causality.

Post-infectious irritable bowel syndrome Patients who, after successful treatment of C. difficile infection with negative cure tests, continue to present functional gastrointestinal symptoms should be coded with appropriate codes for intestinal functional disorders, not maintaining code 1A04 indefinitely.

Other infectious colitis Colitis caused by other pathogens (Salmonella, Campylobacter, Entamoeba histolytica, cytomegalovirus colitis) have specific codes and should not be confused with C. difficile infection, even if the clinical presentation is similar.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnosis of C. difficile infection requires the combination of clinical manifestations compatible with laboratory evidence of the presence of the toxigenic organism or its toxins. Clinical criteria include diarrhea (defined as three or more unformed stools in 24 hours), cramping abdominal pain, fever, and leukocytosis.

Laboratory confirmation can be obtained through different methods: toxin A and B detection test by enzyme immunoassay, glutamate dehydrogenase (GDH) detection as a screening test, PCR for toxin genes, or toxigenic culture. Two- or three-step diagnostic algorithms are frequently used to optimize sensitivity and specificity.

Severity assessment is essential and includes parameters such as body temperature, white blood cell count, serum creatinine level, albumin, and presence of complications such as ileus, megacolon, or perforation. Severe cases may present with leukocytosis greater than 15,000 cells/mm³, elevated creatinine by more than 50% of baseline value, or evidence of severe colitis on imaging.

Step 2: Check Specifiers

Although code 1A04 does not require mandatory subcategorization in the current ICD-11 structure, it is important to document specific characteristics in the medical record that influence management:

Severity: Classify as mild-moderate, severe, or fulminant based on clinical and laboratory criteria. Severe infection includes significant leukocytosis or creatinine elevation; fulminant involves hypotension, shock, ileus, or megacolon.

Recurrence: Document whether it is first episode, first recurrence, or multiple recurrences, as this radically alters the therapeutic strategy and may indicate fecal microbiota transplantation in cases of multiple recurrences.

Origin: Specify whether the infection was hospital-acquired (symptom onset after 48 hours of admission), healthcare-associated (onset up to four weeks after hospital discharge), or community-acquired (without recent exposure to healthcare settings).

Complications: Record presence of toxic megacolon, intestinal perforation, sepsis, need for colectomy, or admission to intensive care unit.

Step 3: Differentiate from Other Codes

1A00 - Cholera: Differs by clinical presentation of profuse watery diarrhea "rice-water stools," rapid severe dehydration, usual absence of fever, and laboratory confirmation of Vibrio cholerae. Cholera is not associated with prior antibiotic use and has a distinct epidemiological pattern, usually related to contaminated water in endemic areas.

1A01 - Intestinal infection by other bacteria of the genus Vibrio: Includes infections by Vibrio parahaemolyticus and other non-cholerae species. Typically associated with consumption of raw or undercooked seafood, presenting with watery or dysenteric diarrhea, but without the characteristic association with prior antibiotic therapy that marks C. difficile infection.

1A02 - Intestinal infections by Shigella: Characterized by dysentery (diarrhea with blood and mucus), intense tenesmus, high fever, and constitutional symptoms. Shigellosis is transmitted fecal-orally, is not related to antibiotics, and laboratory confirmation identifies Shigella species, not C. difficile.

Codes for inflammatory bowel colitis: Crohn's disease and ulcerative colitis have their own codes in the chapter on diseases of the digestive system and represent chronic autoimmune, non-infectious conditions, although they may coexist with C. difficile infection in some cases.

Step 4: Necessary Documentation

For appropriate and complete coding of code 1A04, the medical record must contain:

Checklist of mandatory information:

Date of onset of gastrointestinal symptoms
Description of diarrhea (frequency, consistency, presence of blood)
History of antimicrobial use (which antibiotic, duration, when started)
Laboratory test result for C. difficile (type of test, date, result)
Severity assessment (white blood cells, creatinine, temperature, signs of complication)
Treatment instituted and clinical response
If recurrence, document previous episodes and prior treatments

Appropriate documentation: Documentation should be clear and objective, allowing coders to unequivocally identify the diagnosis. Terms such as "diarrhea associated with C. difficile," "confirmed C. difficile colitis," or "Clostridioides difficile infection" facilitate correct coding. Avoid vague terms such as "hospital diarrhea" without specifying the etiology.

6. Complete Practical Example

Clinical Case

A 72-year-old female patient was admitted to the hospital with a diagnosis of community-acquired pneumonia. She presented with productive cough, fever of 38.5°C, and pulmonary infiltrate on chest radiography. Empiric treatment was initiated with ceftriaxone and azithromycin according to institutional protocol.

On the seventh day of hospitalization, the patient showed improvement in respiratory symptoms, afebrile for 48 hours, but began presenting with watery diarrhea, without visible blood, with a frequency of five to seven bowel movements per day. She complained of diffuse abdominal cramping and general malaise. On physical examination, she presented with distended, tympanic abdomen, with diffuse pain on palpation without signs of peritoneal irritation.

Laboratory tests revealed leukocytosis of 18,500 cells/mm³ (previously normalized), with left shift, and creatinine of 1.8 mg/dL (baseline value of 1.0 mg/dL). A test for detection of C. difficile toxins in a stool sample was requested, which returned positive for toxins A and B.

Based on the clinical presentation of antibiotic-associated diarrhea, significant leukocytosis, elevated creatinine, and positive toxin test, a diagnosis of severe Clostridioides difficile infection was established. The antibiotics for pneumonia were discontinued and specific treatment with oral vancomycin was initiated. The patient was placed on contact precautions, with a private room.

Step-by-Step Coding

Analysis of criteria:

Presence of diarrhea (more than three liquid bowel movements in 24 hours): ✓
Previous use of broad-spectrum antibiotics: ✓
Laboratory confirmation (positive toxin test): ✓
Severity criteria present (leukocytosis >15,000, elevated creatinine): ✓
Exclusion of other causes of diarrhea: ✓

Code selected: 1A04 - Intestinal infection due to Clostridioides difficile

Complete justification: The code 1A04 is appropriate because the patient presents with all essential diagnostic elements for C. difficile infection: compatible clinical manifestations (watery diarrhea and abdominal cramping), typical epidemiological context (hospitalization with use of broad-spectrum antibiotics), and laboratory confirmation through positive toxin test. The presence of severity markers (marked leukocytosis and renal insufficiency) does not alter the primary code, but should be documented in the medical record to guide intensive treatment.

Applicable complementary codes:

Code for pneumonia that prompted the initial admission
Code for acute renal insufficiency, if clinically significant
Code for procedures (contact isolation, if coded institutionally)

This case illustrates the typical presentation of C. difficile infection in a hospital setting, demonstrating the importance of early recognition and appropriate coding for implementation of therapeutic and infection control measures.

7. Related Codes and Differentiation

Within the Same Category

1A00: Cholera

When to use 1A00: Patient with profuse watery diarrhea, described as "rice water," with severe and rapid dehydration. Laboratory confirmation identifies Vibrio cholerae. There is usually an epidemiological context of exposure to contaminated water or travel to an endemic area.
Main difference: Cholera is not associated with prior antibiotic use, presents with much greater volume of fluid losses (can exceed one liter per hour), rarely causes fever, and the etiological agent is completely different. The epidemiological pattern is distinct, with predominant waterborne transmission.

1A01: Intestinal infection by other bacteria of the genus Vibrio

When to use 1A01: Gastroenteritis associated with consumption of shellfish, especially raw oysters. Can cause watery diarrhea or dysentery. Laboratory confirmation identifies species such as V. parahaemolyticus or V. vulnificus.
Main difference: Specific food history (shellfish), absence of association with antibiotic therapy, more acute onset of symptoms (usually 24 hours after consumption), and identification of Vibrio species different from C. difficile. The clinical and epidemiological context is clearly distinct from C. difficile.

1A02: Intestinal infections by Shigella

When to use 1A02: Presentation of dysentery (diarrhea with blood and mucus), high fever, intense tenesmus, and abdominal pain. Fecal-oral transmission, common in environments with poor sanitation. Confirmation by stool culture identifying Shigella spp.
Main difference: Shigellosis presents with visible blood in stool in most cases, is not related to antibiotics, has a short incubation period (1-3 days), and the agent is identified by conventional bacteriological methods. The clinical presentation is more invasive with greater involvement of the distal colon and rectum.

Differential Diagnoses

Ischemic colitis: Can mimic C. difficile infection in elderly patients, especially if there is bloody diarrhea and abdominal pain. Differentiated by absence of positive C. difficile test, vascular risk factors, and computed tomographic or colonoscopic findings of segmental ischemia, usually in the territory of the inferior mesenteric artery.

Inflammatory bowel disease (Crohn disease or ulcerative colitis): Can present with diarrhea and constitutional symptoms. Distinguished by chronic and recurrent nature, characteristic endoscopic findings, and absence of temporal association with antibiotics. Important: patients with IBD may develop superimposed C. difficile infection, requiring both codes.

Viral gastroenteritis: Usually self-limited, with shorter duration (24-72 hours), frequently accompanied by vomiting, and without association with antibiotics. Tests for C. difficile are negative.

8. Differences with ICD-10

In the International Classification of Diseases, 10th Revision (ICD-10), infection by Clostridioides difficile was coded as A04.7 - Enterocolitis due to Clostridium difficile. This designation was located in the same chapter of infectious and parasitic diseases, under the category of bacterial intestinal infections.

Main changes in ICD-11:

The most evident change is the update of the organism name from "Clostridium difficile" to "Clostridioides difficile", reflecting the taxonomic reclassification based on genomic analyses that demonstrated this organism deserved a separate genus. This nomenclatural alteration, although it may seem superficial, is scientifically important and aligns the classification with current bacterial taxonomy.

The code changed from A04.7 (ICD-10) to 1A04 (ICD-11), representing a restructuring in the numbering system. The hierarchical structure remains similar, maintaining C. difficile infection within bacterial intestinal infections, but ICD-11 offers greater flexibility for future expansion and better digital integration.

Practical impact of these changes:

For healthcare professionals and coders, the transition requires familiarity with the new code and updating of electronic record systems. The essence of the diagnosis and clinical criteria remain unchanged, but documentation must reflect the updated nomenclature. Health systems in the process of implementing ICD-11 need to ensure that search tools recognize both old and new nomenclature to prevent information loss during the transition period.

The change also facilitates international epidemiological research, as standardization of correct scientific nomenclature improves communication between different health systems globally. Surveillance reports and multicenter studies benefit from this taxonomic harmonization.

9. Frequently Asked Questions

How is Clostridioides difficile infection diagnosed?

Diagnosis combines clinical evaluation with laboratory confirmation. Clinically, it is suspected in patients with diarrhea (three or more unformed stools in 24 hours) who have recently used antibiotics or are hospitalized. The most common laboratory test is the detection of toxins A and B in stool samples through immunoassays. Many laboratories use two-step algorithms: first a screening test for glutamate dehydrogenase (GDH), followed by confirmation through toxin detection or PCR for toxigenic genes. Colonoscopy can reveal pseudomembranous colitis in severe cases, showing characteristic yellowish plaques, but is not necessary for routine diagnosis.

Is treatment available in public health systems?

Yes, treatments for C. difficile infection are generally available in public health systems in various countries. Therapeutic options include specific antibiotics such as oral vancomycin, fidaxomicin, and metronidazole (the latter less commonly used currently for severe cases). Availability may vary depending on the region and the level of complexity of the institution. Mild to moderate cases can be treated on an outpatient basis, while severe cases require hospitalization. For multiple recurrences, advanced therapies such as fecal microbiota transplantation have become progressively more accessible in specialized centers.

How long does treatment last?

Treatment duration varies depending on severity and whether it is a first episode or recurrence. For mild to moderate initial infection, typical treatment is 10 days with oral vancomycin or fidaxomicin. Severe cases may require 10 to 14 days of treatment. For first recurrence, a prolonged course of vancomycin with gradual dose reduction (tapering) or intermittent pulses is used, which may extend for several weeks. Multiple recurrences may require even longer treatments or alternative therapies such as fecal microbiota transplantation. Clinical response generally occurs within 2-3 days, but complete resolution may take one to two weeks.

Can this code be used in medical certificates?

Yes, code 1A04 can and should be used in medical certificates when appropriate, especially in contexts where C. difficile infection justifies absence from professional or school activities. Due to the risk of transmission through spores, symptomatic patients should avoid collective environments, particularly if they work in food services, healthcare, or with vulnerable populations. The certificate should specify the period of absence necessary, usually until resolution of diarrhea and possibility of adequate hygiene. Appropriate documentation with the ICD code facilitates understanding of the infectious nature of the condition and justifies necessary precautions.

Is C. difficile infection contagious?

Yes, C. difficile infection is contagious, transmitted via the fecal-oral route through spores that are extremely resistant and can persist on environmental surfaces for months. Transmission occurs when spores are ingested, usually through contaminated hands or contact with contaminated surfaces. In healthcare settings, transmission between patients is a significant concern, justifying contact precautions (use of gloves and gown, private room when possible). Hand hygiene with soap and water is more effective than alcohol gel for removing spores. Patients should maintain rigorous hygiene and avoid sharing bathrooms when possible during the symptomatic period.

What are the risk factors for developing this infection?

The main risk factors include antibiotic use (especially fluoroquinolones, clindamycin, cephalosporins, and broad-spectrum penicillins), advanced age (over 65 years), hospitalization or residence in long-term care facilities, gastrointestinal surgical procedures, proton pump inhibitor use, chemotherapy, inflammatory bowel disease, and immunosuppression. Duration and number of antibiotics increase risk. Patients with a previous episode of C. difficile infection have substantially higher risk of recurrence. Understanding these factors is important for preventive strategies and early case identification.

How to prevent C. difficile infection?

Prevention involves multiple strategies: rational and restrictive use of antimicrobials (prescribing only when necessary, for the shortest effective duration), rigorous hand hygiene with soap and water (alcohol gel does not eliminate spores), implementation of contact precautions in confirmed cases, adequate environmental cleaning with sporicidal agents (such as sodium hypochlorite), early identification and isolation of suspected cases, and education of healthcare professionals and patients. In healthcare settings, antimicrobial stewardship programs demonstrate effectiveness in reducing incidence. For patients with multiple recurrences, restoration of intestinal microbiota through specific probiotics or fecal microbiota transplantation can prevent new episodes.

Can the infection cause serious complications?

Yes, although many cases are mild to moderate, C. difficile infection can cause potentially fatal complications. Serious complications include toxic megacolon (severe colonic dilation), intestinal perforation, sepsis, acute kidney injury, severe electrolyte imbalances, and shock. In fulminant cases, emergency colectomy may be necessary. Mortality rate is higher in elderly patients, immunocompromised patients, and those with significant comorbidities. Warning signs of severe disease include marked leukocytosis (>15,000 cells/mm³), significant elevation of creatinine, high fever, severe abdominal pain, abdominal distension, or signs of hemodynamic instability, requiring urgent evaluation and intensive treatment.

Conclusion:

Appropriate coding of Clostridioides difficile intestinal infection using ICD-11 code 1A04 is fundamental for adequate clinical management, effective epidemiological surveillance, and implementation of infection control measures. This article provided detailed guidance on when to use this code, how to differentiate it from other similar conditions, and the documentation necessary for accurate coding. Clear understanding of diagnostic criteria, risk factors, and clinical manifestations enables healthcare professionals to correctly identify and code this important nosocomial and community infection, contributing to better clinical outcomes and more effective preventive strategies in health systems globally.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Intestinal Infection by Clostridioides difficile

Partager